Adaptmet Deconstructing adaptive evolution of metastasis
- Coordinator
- Fundacio Institut De Recerca Biomedica (irb Barcelona), Spain
- Runs
- 1 March 2025 to 28 February 2029
- Status
- Running
- EU funding
- €3.5m
- Total cost
- —
- Partners
- 22 organisations in 10 countries
- Type
- Marie Skłodowska-Curie Action
- Grant agreement
- 101169223
What the project is doing
In the project's own words, from its summary on CORDIS.
Adaptmet aims to develop an advanced training program encompassing the multifaceted aspects of metastasis adaptation mechanisms, intending to equip budding researchers with the necessary skills to emerge as leaders in this field. A robust mentoring and training strategy, coupled with cutting-edge methodologies and a diverse range of complementary soft skills, are crucial to this endeavour. These skills are imparted through local and network-wide events, fostering seamless research progression, and nurturing successful career trajectories.
Scientifically, Adaptmet addresses an unmet medical need by harnessing basic science to revolutionize drug development and, ultimately, enhance patient care. Specifically, scientific work packages (WPs) have been designed to approach metastasis from various functional perspectives. In order to metastasize, cancer cells must adeptly coordinate diverse cellular functions (Cell Fate - WP1). Additionally, understanding the intricate interactions between metastatic cells, the host immune system, and tissue stroma is pivotal (Environment – WP2).
Crucial aspects such as the kinetics of metastasis and the mechanisms governing latency, particularly, remain inadequately understood (Latency – WP3). Clarifying this complexity, unravelling mechanisms underlying therapy failure, and identifying expansion pathways are central to defining novel therapeutic targets (Expansion – WP4). In essence, Adaptmet stands at the intersection of a rapidly evolving multidisciplinary domain, amalgamating distinct fields that often face challenges in mutual communication.
The success of Adaptmet hinges upon robust partnerships, open exchange of ideas, state-of-the-art methodologies and equipment, and the exploitation of synergistic opportunities among network members. This collaboration spans diverse perspectives, bridging gaps between different disciplines, thereby breaking down barriers and fostering interdisciplinary cohesion.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Fundacio Institut De Recerca Biomedica (irb Barcelona) | Barcelona | Spain | Coordinator |
| Boehringer Ingelheim Rcv GmbH & Co Kg | Wien | Austria | Participant |
| Forschungsinstitut Fur Molekulare Pathologie Gesellschaft Mbh | Wien | Austria | Participant |
| Universitat Wien | Wien | Austria | Associatedpartner |
| Cancer State Therapeutics | Charleroi | Belgium | Participant |
| Universite Libre De Bruxelles | Bruxelles | Belgium | Participant |
| Universitat Basel | Basel | Switzerland | Associatedpartner |
| Universite De Lausanne | Lausanne | Switzerland | Associatedpartner |
| Saso Kocevar | Heidelberg | Germany | Associatedpartner |
| Danmarks Tekniske Universitet | Kongens Lyngby | Denmark | Associatedpartner |
| Zs Associates AS | Kgs Lyngby | Denmark | Participant |
| Fundacio De Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi I Sunyer | Barcelona | Spain | Participant |
| Fundacio Institut De Recerca Contra La Leucemia Josep Carreras | Badalona | Spain | Participant |
| Fundacio Institut Hospital Del Mar D Investigacions Mediques | Barcelona | Spain | Associatedpartner |
| Gr Espanol De Estudio Y Tratamientode Intensific. Y Otras Estrateg.experiment. En Tumores Solidos - Grupo Solti | Barcelona | Spain | Associatedpartner |
| Scienseed SL | Madrid | Spain | Associatedpartner |
| Universitat De Barcelona | Barcelona | Spain | Associatedpartner |
| Helsingin Yliopisto | Helsinki | Finland | Participant |
| Academisch Ziekenhuis Leiden | Leiden | Netherlands | Associatedpartner |
| Stichting Het Nederlands Kanker Instituut-Antoni Van Leeuwenhoek Ziekenhuis | Amsterdam | Netherlands | Participant |
| Lunds Universitet | Lund | Sweden | Participant |
| Institute of Cancer Research: the Royal Cancer Hospital Lbg | London | United Kingdom | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI